<SEC-DOCUMENT>0001193125-12-017176.txt : 20120119
<SEC-HEADER>0001193125-12-017176.hdr.sgml : 20120119
<ACCEPTANCE-DATETIME>20120119170428
ACCESSION NUMBER:		0001193125-12-017176
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120119
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120119
DATE AS OF CHANGE:		20120119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		12535250

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d285823d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): January&nbsp;19, 2012 (January 19, 2012) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;19, 2012,
ARCA issued a press release announcing that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype. A copy
of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements
and Exhibits </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA BIOPHARMA ANNOUNCES ADDITIONAL PATENT ISSUED FOR METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENOTYPE
OF PATIENT,&#148; dated January 19, 2012.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">.</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: January&nbsp;19, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVP and General Counsel</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA BIOPHARMA ANNOUNCES ADDITIONAL PATENT ISSUED FOR METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENOTYPE OF PATIENT,&#148; dated January 19,
2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d285823dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g285823g75k87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com
</U></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES ADDITIONAL PATENT ISSUED FOR METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENOTYPE OF
PATIENT </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pharmacogenetic Patents Have the Potential to Extend Drug Candidate&#146;s Potential Commercial Exclusivity Period If Regulatory
Approval Obtained </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, January&nbsp;19, 2012</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based
on whether the patient has a specific genotype &#150; homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor. The patent (USP# 8,093,286) entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting,&#148;
provides intellectual property protection in the United States for this novel approach to treating patients with bucindolol. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are
pleased with the USPTO&#146;s issuance of this patent, which we believe extends our pharmacogenetic intellectual property protection around bucindolol,&#148; said Michael R. Bristow, President and Chief Executive Officer of ARCA. &#147;This patent
provides protection for the means to identify patients with a specific genotype, which, based on data from a prior Phase 3 clinical trial, we believe has more favorable cardiovascular responses to Gencaro as compared to the general population of
patients with all genotypes. In a planned phase 3 clinical trial, we intend to evaluate bucindolol as a potential treatment for the prevention of atrial fibrillation in patients with this genotype, which we estimate is present in approximately 50%
of the U.S. general population. We believe an important benefit of a pharmacogenetic approach to drug development is the potential for extending a drug candidate&#146;s potential period of commercial exclusivity, if regulatory approval is
obtained.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>.
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements regarding the issuance of, and protection provided by, U.S. Patent 8,093,286 entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting&#148; and statements regarding the potential for pharmacogenetic
patents to potentially extend a drug candidate&#146;s commercial exclusivity period; the ability of genetic variations to predict individual patient response to Gencaro; the potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment; and the Company&#146;s ability to fund future operations, including, the proposed clinical trial to evaluate bucindolol as a potential treatment for the prevention of atrial fibrillation. Such statements are based
on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation,
the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by
the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail
in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these
forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g285823g75k87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285823g75k87.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/`"L`P$1``(1`0,1`?_$`+8````&`P$!````````
M```````&!P@)"@($!0,!`0$``04``P$`````````````!P$"!@@)`P0%"A``
M``8!`P(""`0#"`(#`````0(#!`4&!P`1""$2$Q0Q02)B(Q46"5%A,A=QT22!
MD:'Q@D,8"K'!0E(T$0`!`P($`@<%`@D-```````!``(#$00A$@4&,0=!47$B
M$Q0(88&1P3*AL='A0F*2TB,5"5)R@J)#@R1$)187&!G_V@`,`P$``A$#$0`_
M`+>G+/E7.8QF`QYCL6Y;4=F@\FIIT@1VE!-W9.]DV9LCAX:S]TD`G,<_<5(O
M;[(B.VN>WJY]7&J<J=6CY<[`CCEWA-%GDD<<(6D$TX&CLHJ.T*6.7VP!N#_4
MM3PTT5H#4!U...&%11,J@<I<B[4^$A,K7E%V[,HHDBWEET$C+@43@W2;H))-
MDBF*'LD*4!USYVUS?]3>\]4RV.[->ACF+WD>:>&L+6DY&88,PP"F67;NRK*,
MOET^S=&11I+!6HQ)1U2L_(-2'5DOW8OX$0>(M3G-.NR#_4-%G'=VB&X]H(&$
M`_`-9M_N/U7^19?#=VO5,A;E\T_B#0?%?!BMMCB0YM/LB!^8$19[*'(RMK)"
MME:_^.0J2P)+2RQTP,OVKHHKI+)G2[A3,'LG*.X#MMK"]Q\W?5)M6^ABEW5K
MDK\'N:;E]*#'*<.&"^Q9Z#LG46.8S3[-KW<.X*CL3N>*_+6R7FPI8VR:=->=
M>E7"O6-)(&1Y!PUV55BI-N@0K0'8HB84E4R$*H!!*8.[J.[OI2]9.L<Q=QLY
M9\R(S#JCX<UK<`]^8M+JB0T%22TCLHHJW_R[&AV9U.P%(.):.`ZJ5QX]'"BD
M6!53<0[AZ?Y=/RZ:Z8!KFM&8@NHH>9C`UQ^I9`=0>@&'<=%1,9YG<\<:<+I+
MC[$WQ!>1>9XRW$8[11;R"#$]6J[I1%K8<B2!54E3N(RL/)%B0Z)0(97S(B4W
ML"&B)\H*G$`$#]P"`"4P"!@,4>I3%,'0Q3!U`0](:(M.1=O6K!ZY9-%9)XV9
MN7#6-260;K23I%$QV\>DY<F(V;'>*@"8**&*FF)@,8=@'1%#5R!^\E&<3I>'
M@>2O#KDGBU]8F[]Q7WJK_&-DKLZG&BB$B,58J]<'<<Y58G73[TQ$BA2*`;L[
M1T1*[1/N&9IR=0H;*./_`+=G*:?H-BBD+#!2R]CPM#RLU!ND2N&4A#UJ5O+>
M6>HOT#@=$HD(=0A@$.@AHB/G%G[FG&_E7=9G$D"]MV,<XUQ>1;S>%<OUU:G7
MI):),(2B$:D==Y'32\9ONLFW<"N4GM^&*?M:(I"0.<=Q`PB`&$HC^!@](?V:
M(F-\K?N(<;>(DA$5&_V6:MF6[,9FE4\(XOAUKKE*?</SBFP`E>C^[Y6@^.``
MF=ZH@"@;F3`P`.Q$48;DISQNL82Q57[?B%8A71/,QD9F#DI3Z=>G+<VQB_,*
MO7ZK;6L&X4(8/@N7H'2$=C``Z(FOW;[P5IP-E2BXAY3\(LU85F[[:H:L5VUM
M[G3+ECZ44FY=I#ED8RU,@C&,LTC5'8*.4DA,Y22`1%+NT138]RA3=HF-[.X"
M(_\`R_2!1#^PO7\QT19`<XB`=P]1`/[]$3%,(\]L:9PY;<D.)==051LG'IC`
MN36$9%NY871=;L:7AI&-")$5;*4.;<MFBQA.<%C+F$``$QT1/J\0_P#]A_RZ
M:(O7O-X6^X[]VV_]NB*$7D#"EF^3F3R++>7`LI#HD76,8R`)C7(3=(YB=YTB
M"/N[%Z_CK@?ZF-";N/U3[DTZ=I\(W]OB'=XCR=KW1AW1QZ^-5M=LN>.UV-82
M/=5OA/JWA_:/Z?Q)SN/,;IMHDCZ51;Q@19$I)C<"*MG40<K$GC@TF%FAQ22(
M!"B5-0`!4H#V"4=];:<L>4%KI^ELNM9B\EI]NULC;G!V9K<71EN%*@'O9L2Z
ME%'6X-9NY+_P;=Q?%(2!&.+?S@>FO"E!PXI8XN-H=D,Y3CXB67AEYYK8%3$9
MD!L?PFYB':-R&6!P,:N=8Q@Z`;L'8`U-NE6>P-?S1Z9%<&T\5KVN$0+08B"Z
MO>P#BTX]`-:%89+>7=K"^25_[0'+3Y]J2[)N+CF1?23%J5^^E%%Y*0G%CH-(
M.-0>*F%-LQ</C)H'<`0.TYC["F``0H;]=1=S5Y06ES8NO=.M)9C<9O\`$.:&
M,A'5Q<74_HK)=O:Q(^5A,GAY:8<2?NHF7XZ@!@N0F+B-W)5E/KF*365;&$4N
MPQE]P344*CWDV'VA+OW?GOOK1WE1H,VU_45MVWM[EDN?4X6$M;5N1\P86M->
M'$DTXDBG2I8UZ\=J&U;IT_>;Y=SA[*`CY54Z@D[0W$=Q$?PVZ;;[>D=?H`#:
M.<:X$_#`"BU+;@W#Z22?DOFPCT#H(]`'?;8?QWV';;5RJJB7W0<7V7G+CSES
MS>@7TD\H/%+)4)@K"S!FL<8N:QU0I!6-Y%WUD@F7Q'*CC(4ZCY5T0=BM(,^P
M^L"*>'[67)?_`)4<(L,WZ2?$>72MPPXQR(/>!E/K.A$1B'+I40,8QC3D45J_
M`P_J!SZ1](D4AFB*L%_V;2C^U?%(Y3"4_P!;98)N(=P;&IL04`$AMR"``(^K
M<>G7IHBGXXD=G_%;C5N4H`.!<3;B`F$``*)"]NXF,.Q0!,-]NHCZ-$56/G;"
M3<S]^W&;#`;113(Q+;QSEIPU=3V5:S$:T9.[I)RBS?\`_.V:8_*F,BJ<2@+<
MXE5W[@`2*R']Q/E?_P`,^)F4\X1Z"#NWM&S&JXX8O2`=D^O]J>*Q=>4<)&]E
M9E#@9617*.P'19F#UZ(HD_L/\8%+C"W[[AF<5W=_S5EBX62%H]LM0GDY".AH
MYX+.VV]JH[*?RTM9IPJ[-!5+L!K'M/!0[4E#%$BLE?B.XCOZ=]NOX&$0V#NV
M].P``^GTZ(FR<M^+].Y<X4L^'[>LA%KOU8R=I=O"-3D)3']ZK[UO)UVWPY3K
MMC^:CWC4I5$RJI`L@8Z8FV,.B)R;))V@P9(/5@=.D6K9)T[!/PBNG2:!".'!
M$^\_:1=4#'`-QV[MMQT1-HYE<A&W%WC9E+,GEP?V""@_E%`@R]IE[+DJU+HU
MV@5]HD8/ZE61L\DW`Y"[CX13CZM$54RST&W_`&C?N.<1LJ6V>E):!R]2Z]+Y
MHL3Y4S@LI8;\Y/!<@6[A0`,15&'M4PC*M2FZD2\,>G;OHBNG(JI+(I+(*IKH
M*I$4072.51-=!0H'1634()B*$52,`@8!$!`=]$6U_L_ZM$4.66G+5+E#DXJK
M$'QAF(<ID]W("(#78/V`!H('$3;[``ZX=\X'V;?5QND7=N^XD=J%LUC2<K2?
M(VM`#C]RV1V\QIV-95=0^$_#^\>G'2D4_E,06N%KD0PC;*X8L'K.!CI=T_FI
MMO%2#>1?,56HN'#9!PX:-S=@'V$P@!?7K;;7-*UG<7)K5MN[0AM[/=LD,#XX
MHYS+.]L,@EE8&>&P-K&#^4:UI18'&6VFX;:2X-;9TC@7$4:VHI6J+&-<ZQ<9
M'^54<E(\3*1`[-=+R[XJVP@9!1H(%<IJ]X"'8!0,`]`#6$\KN>MAH-LZS>Z6
M.Y+60O9E/[.5E&O#QA]1X\>*^CN#;KI)G3!I%KG#LW13`D]E$L=A4,\IK,LE
M%QSV55.ZDDH.3E7<7),F<@<%F146WCMT'"BJ0=XE$>\HFVVU/>ZM1)V@V;5K
M6V?J\P,@BDN"R7PW<'"+PG#*14COK%K*U\+4`8''R]?J&(P..*8W`.VZG(+%
MJ7RTL>Y"_0Y3)%4=J')L=8.PWFC'#^X=<[MKF+_LUMQD3&Q-;JENXL'!@$X<
M[W`=XJ9[H!VR[J2,YH6VKVEPX`T=A]JFE/Z/[?\`UKNSF!)`Z_D%JTWZ1[_O
M*8=]Q[D3+\<.*EXG*64SK+F2'$5A;",6CVF=R&4\H+J5NNJM2%,!SC"E75?F
M'8P%!M[6P#JJJFHX<H7+#%G$6O\`$!;@16)^E,L7/L<V=^XY5T1-Q;7=E8.D
M[I9GB2M166![8IJ6=O3`HH91-10`$PB`"!%&!]BO(]NXQ<P>0_`3+;<]>DYY
M5_(1,&YD"/TF&3,9HF3EH]D_3%-O($GJ(J1P5=(H>;+'%4VV.&B*VU^7KV`=
MO7L;?M'^`[#HBK"_]FK8,5\4!'80"]Y4$0'?80"H0XB`]OM;"'X:(C5GM]]S
MWCG]O3$V;L#<FH2XT&$PKCB3MU5)@REL+[CJDR%.C"I35<L::LHWL,;4D5DR
M.U%61'9&Y1<[F`IP`B<#]D-;BSE##L]G2BUYR[Y72<@I$\GKID">6NF3WUO>
M'*\4E&T_)`#IE2+@`"[:(-$D42]AD%/$.AW"1%O_`+%L%.2'"B@S,7WFB*WR
M"I[JQI)E.=,B$G7K9&QKMR!0$A$49=PD3O/T`ZI0](AHB=3]EN>A9[[:O&I.
M%%$QX"*M]=FBIF*`HS<9?[*I(`L)!W!=4'::H`;81*<!]`AN12E:(@(@`&$1
M_2`";U]H"`B&^WHW`-$0'ION`AL&X[@(;!T_GHBA`YN7/)6>^=F`>.>&L9ML
MW07$Y)ARHSC1W=YB:!"/;B]\Q#X5A):PS$=)L16A'ASS/DQ3,9;O(.VQ-$34
M_O.4'E3R0XMENF0N(,1C)+`$TOD)S>8C/M2R"_95:09_([7'$K,97(Z2=(.$
MW#9T(IJ]J7D^\0V`1T129?:(Y+GY.<&L4S4O(E>7O&K4,07X3*`HX-,TI!)M
M%2BY1$50"=K"K%QN;TJ&/L([:(I/_P#9_P!6B*#_`)4*2M3Y)WQPY%5HC-*0
M<HP-N=%-TQ6A(]F"H*IE#O3*Y8J)G]H1*;8!].N!/K"M]3VGZF-7U2\=-':7
M]Q#/`0"`0RU@C-#7'O1D+;'ETVPU;9$%K@9X(W@]N=Y^:4/%N546Y&L1'O/*
M!)"D2;FB#V./))["HR;"0Z7E6J21>XXD$%%C`&Y@#IJ4.4/.N.S=:64;A%.]
M^:Z>]U7/A`[H;[P:^Q8WK>T8;N,3R%P<QSLE.NB<$IERN*`\MA(&NF?HVAGY
M98T3'#(&AB-G'<07IT#.P76!(!,IOW=YMPUL++SCV=;13:^^PL?/LN6!@#6T
M=""WQ"</JRYO>L+9MR]<#"Y\I8&FF)IF_`D1R=EEFZ!]&NG8NF""AU:_)']I
MZT:O!\VBV4,*AA7:"!P*)!$#)J%[@$/1J#^:G/*WN?$TNXE'=898'M/$.!I$
M#[.%%F&WMLY7`S@"O'VI"<&'E[KR#QHDV.J_&-LZ,PYZG5*VCXPCEPX=K'$H
MB5/8H>T(]3'#6OOIMCUW?GJ#T6XLVND;97C99">/AAV8U]P(66[KDM=&V->6
MXH`_#X@#[RIP;!882K13N=LLW#UZ$CR>(^EYZ390\4S()@*4SJ2D5VS%J4YC
M;`*BA0$>F^OT'QE[B\N%&Y\/:,H^=5J8YT9`#.U5Y+AS"XZ\Q?NXX'Q\?+U"
M)@CA_6[KD*!FI2TQ$?5LE\C5$&T6T+!23YRVC91*E1SKO;G!0Y5G+5<43&#K
MKR*Q6)4'C9VS3?MGC1XV7:E=MG;98B[(Z2I$U4G*#Q,3IK-%@$#"<IC%,4>[
M?;1%38^\-?L?\=_N6X*Y:X,OU.L5N/&5.^7B#J-BA955M8<>2Y:ZN28&*<N4
MVYKU2E09'(J)3G*W,)B["!M$5J'CURZX\<H:/"WO#64J?:6,M#IRSV"0L$2E
M:JR<J1%9*/M%;5<$FH5Y"'4\)P"R14B=@B!A*(")%6^_['F>,-Y`@>-N.J-D
MNDW.VUB?R-8;+$U2R1,^K7XJ5@(>)C5I96,=.6S-:0?@8B*1U`4-V"(E`.NB
M*>7@KFK!.<^)N!JO4,@XZR`8<%TFI6VF-YZ&DI=!6+I<?!6J#GJL=P:313;J
M>,@Y370`AB#ZRFT15G\M0M]^QA]Q>+R-1V\L_P"+V6EG;MK#F<_T-DQ?(/\`
MQK1CI=9011^L<6RCE-Q$J*#W*(&0']"KC8BLPS]NXB?<PXY7+%-3RQ1\A5#+
ME07;BVKMDB7%RK;I(B<E'32]54=)3\3.5.71;.#)+MTQ*JGVB/:.^B*"[A)E
M[*WV8LRW/BWS5AI>-XRY)LZDW0<^Q<<]DL>Q5G4%-E]1B_:HN$&%?L\4W;A*
MLC`5]$O2%.9,R)N_1%:-I^1:#D&!8VFBW:I7&M22!'3&?K-BB9J(<H*IE52.
MB]8.UD3"8APW`1`2CN!MM$49WW#_`+KV`N&^.+/%U:YU3)/(B1B';.B8RK4N
MQGUHJ:<H+(MK!>%HTSEO!0\0J/BF27.#AT8H))D]H3E(E6J/(W'_``[X1XIN
M'+#,[!6YQ&$Z[:K>K<[8T<W^[VV;A`GGT7"Q;MQ\VFGCZ8?G9M"))G(D0A2B
M8")F,!$SW[*F0Z)E^E9ZY)3U^ILOR$Y19[N5KNM22GXE6VU6K5@1C,?T[Y*#
MH)-..B*\05R"1(4!(IN!A[1V(IB\L#CASCVUU_*\W68*BW"!F:A/NK9-1,%%
M+QL_&.V,BV,]F7#5H"@L%%#@'=W`!!$/1HBIO_9SYGXMX3<KLWX`R'DZOM\%
M9&L,C6:]D=23(:FIW*B3\G%U*SN943*-FT';*R86YGO<"`&\`RA^S8VB*Y=^
MZF,/HWZ]_<B@?0WB=GUI]95WZ1[^WO[/J3YA\G[NSKMXV^WJT1$7-N`*5F]D
MFA8DW$?-1A%`@[+&>$23C_&`!4;G!;O2>,U#AN9)0O;OU*)1ZZ@;GAZ>ME<]
M].BM]RQF+4[9A;#<L(\1C22:#`$"I/3TK*-M;SU7;$SO*%PMG?4TDY7?@/1T
MU3/$OM\RS)=4T9EQ--N?N(0'%74!;PC;@8JGA3!$Q,8!ZB4-AUI4[^&XZTO?
M'T?=+H9&@AKY+7QI,I_)J9V4^VO#!2.SG*',$<EBUX'41QZ^"[`\&+3Y=1N.
M7FIBG."@F&M.0]HN_:(@$UMN`"/]^O:_\\MRNB%J[>M;8&N7]W"F/'_-\2KO
M^7X.'[N_K#]5<-?[?<V^4(#W+;=1$!`IC)UA<RH)"<3'(F*DV``([CMUZ#ZM
M>H/X;5W>7D3M9WE</MX35@%@"&_S:W>"#G!#'].G4/L</U4['"?'2D812<JP
MH.9BPOTBH25FDQ2%^JV!0%"M&B:1018,2B4!,0A1,H(`)C#MK<3D5Z9]A<C0
MZZTA_GMU21EDEU)&(WN!K@UH<_(*&E,YZ3TT4>;IWS>[CD=$_,RU+JB($Y0:
M4QZS[@`E;NM$I&2:^YJ60ZC6KS5WZ[1R[K=LAF$_"O'$>X(Z9JN(N30<LW"C
M1RF4Z?<01*8`$-;$M+VCPY*F3C[,>I89$W**=*1A3CIP[FUU::?!7'64>LF9
MG+BO)XUQ\\<LF::J;;Q7#1*'44:)@J)2!W]H[]`]>KEY4OK:+@X2%;PS2/C(
MJNQ<8E&-HQ%NW9PT?#,6OED6*;8I2,VL:U9%[`)L5,J8;>C1$C$-Q6XK1S<%
M(7CM@9%N\`KCQ6>+J*HD[*H'>1?Q@AE"N2J%-N!MS`.^^_71%V8#CAQYJ,TY
MLM3P;B.LV%[%2$"\FZ]CVJPTHZA)=$K>4B7+V-BVSA>.D&Y`361,82*$]D0V
MT1<>)XG\6(-+P8GC?@F/3/U,FUQ11R)B)=P`3@$()>X`-T$>NVB+N5CCSQ_H
M%D"]4G"V)J5;F[1ZT"V5FAU:O3B#!\F1.00^<1L:T=IMG22)2J@)^TQ2[#TT
M1="QT_#&;6S=K;ZOCC*[&JSAU&B-AA8"YLX&P&:$36.T+(-G[=E(BR=%*<4]
MC=A]C:(M>MX`P/2K0A>*7A?%-1N39HYCV]IJ]`JL!/H,'B?A.V:<K$Q;1Z5L
MY3`"J$[^TP=!#1$?+)6:W<89[7;=7X.TU^13%.0@[%$,)R(?)B'Z7<9)-W+-
MR'X`8@_EHB9F[^VAP)>OG$@/%C%;!9T85':,#%R%:CW(F$1'Q8F!DHR*6[A$
M=P,B(==$2P4+B-Q8Q>0"X]XZ88J1O9W<16.:JD^,)?0=1\>.6=JJ#ZS&4$P^
ML=$1TM6!\'WVP-;7>\/8PN=F81Z,2QG[71JU8)9E%H'641CFCZ6CG:[9DB=<
MXE3()2!WCTZZ(M*`X[X`J-J87>I81Q+5KC%)N48RTUO'U5@IY@D]0,V>)LY.
M+BVKI`CEN<R9P*8.XIA`?3HB-=]QAC;*\.A7LHT*G9$@&D@C+-86[5V)LT4W
ME&Z2R*$@C'S#5VU(\11<'*50"]Q2G$`'KHB(8<6>,(,AC@X[8+\B*8I"U_:F
MC>"*0B!A3[?D?Z#"`;AZ!VZZ(NO_`,=./_[??M9^RN*OVR^<_4/[??0E:^B_
MGWB^+\W^FOEWR?YEXGM>-X/?OZ]$2NJ![9_S$/\```_\Z\8C#'&2(!LCN)I6
MJN<XN8&#"BPVZCZ-A]6W\MM5I*35SZGLP^%4)!:&FH(ZC1#;^'^/\]5H_P#E
M?8K:-ZW_`*7XD-OX?X_SU?F=2@)K\4HWK?\`I?B0V_OZ?X;?RU8[Q',+7.[#
M3$*V-D;'F2E2>M:SQRU8MG+]ZN#9HT;KN'+@Q@(F@V0047<+G$1#M*BBD8XF
M]0%U5A>(PQYS.'3P5`RDA?7NGH4?F&<JPT58)7)RU*GW@<@,KH5IM9&#)DTA
M*_%%4<QU0C3F5427EG#M)%1VY\J4Y2F4W.<3@8-55Z<_G'(E7IE76B;-5I2[
M(6E9A6'-;BBE*5^A9GA(DC99RNHW#=P94=T4Q,L)"F'8"]=$1BL-GI^&J=!-
M/(KH,D3Q=2IU3AD3NI24D%4R(15?AVZJ@BHL!"^V=0X)HD*)CF``$=$6Q3,A
MMK;,6VM+Q:\)9:0[BFMABE7K203;A.1Z<G%N&S]KVHN$5&PF!0-@.FH02[&#
M8=$2`V;D-8HS(5Z>0M9DIK%N(:NT5OOA(LXJ:^HI18ZI56OS<Z"SIM$PR)E!
M0(`&4%0!#U;D2\73(<+!8EG,E%$CF%+2SV-D1RF`)O"2,:*T0T6(H(D$SYPN
MDD8H[["?<>@:(FR\?;M%8SK&%\=.*?-@&35I9\6YH(QS:$>W2324L4J5K'BH
M256CFJ2OEDWGAE0."7L=Q?:T1/`L5IC*UY)%WX[J3E5E6T/"QR0NY:6<(E$R
MI630HE,*+<NPK+'%-%$H]QS@'I(B7CC*J&14+I((UR3@HBH6!_7"2+]RS>A,
M/(9'OG%VA(PSE+RD>Y`42G*HIXQ@]G\-$2;H<F4963ND)6<6WVSS5*E8QB_B
MHLL6+T6+]--5>4<IK.DRQ_DR+%_I3F%RH/<`$#L/L1'S+V9X;#U:&Q3$/)RH
M_P!$(QS!1L@J@5X\18`9T[=F(S2$CI8"`0ICJJ"!A*42E$VB(FK<EX=*U2E1
M^A[<,DUII+M%E.,4BI+19TU%A%TBL\(-<3(V1,J*C\40\,`,(`!B[D2O8VO+
M;(]!K5^0BI"":62.^9)1TH*0.6;?Q%B%576*)43-E")>(FH'0Z9@,'0=$1"L
MF=HJ+>U-A7ZU-6L]TM*55K[YHO'L8N0<)#XDQ(M5G*WG'4/#LR'.HY(@*)SE
M["F'??1$NO3U;[;CMOTW#U"'Y&#J'Y:(O;_9_P!6B+!3]9OXZ(L-$0T1#1$-
M$2/9\KMQMN);?6J(5-2P3;-".!N=VFP.[BW#M`LTT;O5O@-G3J+!5,ASB``)
MO2&^^B+B5C&[MY(4F1L$$UK-:QHP(VQ[CYJZ0D!CI+RI8\]EL3]H(,74FBQ$
MY&J*(*)HBH=4YS*'``(N?=J1?KAFZD2QV$6&.*'%JS$6[>/B'`]V?N#MW#]2
M#(!7+IS%PY!29^(8B!#KBJ(B)0#1%U<G4^R2F0\47Z*AS6:/Q\-O46K2<@R8
M.#3$Y$),H>637?K(MS$9*$.10>XYRE5$Q2FVVT1>%`JRN)*UDK(^07[%>T6A
M[)W^].V'<$7',XYHJ=A6XLRVQUFD-'I^"50^PK*',8-@$-$2!X]QW?<B8BE(
M>8A@@RYUM+C(&1+BY?MSN#U"9<M7K."A8],XR0RZ\.U1:%!<$T6R8F/W&$2E
MT1.$S!C23O=>H6.H=HT1HB5F@E;P51\#90:;6$`=-(9LB78RYI5\V014*78"
M)@(CN'31%]KM0L5KMM5OM\JT?3C8^B9>)I],9RK.<2;OI0Z+-Y8C/6:23),I
M8AHF@R0`@&1`Z@F$.@:(DTO=6Y`/;-FJ7JL7#@[EZU&P&,;,YGVQ74;"$:D4
ME8:+BE$^V.E)245466>N%"E+X9-NX2EV(EBQ-4)K'6+8RL#',!EH>)6491K=
MT4_B2@H*.3EEIE7M+(24G,G447<E2*D`J]-RE`1(N=@3&3O&M*.E8"(+7FVR
MCRX7V115!P5S99A95RNU3<?J5;12:H()&#V1V$0].B+0R'CN?R-DJG&GF#1Q
MBN@LEK6A&B^0%:VY!`WA0[.09F3$4(R$0`5`.<1(=4X`(;!HB1&;PCE!Y2IU
MRO&,I+(^:;NT/EAPWGFS0L!C9L[.HWI\-**`(D8$CFR#9;RY=S]YQVZ`.B)<
MLKU:^/,.(5&C,H]W-'/68F4C(YX%<:+55H]1+-QD2Y>F6!B16+2\N03"*GA&
M,(]1VT1$:M8YRFOG)*\VF-KS&J5NJ1\#26+%^5W'UIF\2(,^PB(\H(.EI94K
M=)N+U0$2%*!A(4Q>T-$3LPZ?Y[]?7UV#<-_R#1%[?[/^K1%D?PNX=^[??KMO
MHBQ^#[VB(?!][1$/@^]HB'P?>T1#X/O:(A\'WM$0^#[VB(?!][1$A/(OZ)_;
M*9_<'Z[^B/#-]3?0V_F?EVZ>_P`V\/\`J/EGC=O=V^SW?K]G?1$JM3^7_3$!
MY'YAY#Y2Q\A\S\KY[R7@$\IYGR7]+XGE^W]'3;\]]$1A^#[VB(?!][1$/@^]
MHB'P?>T1#X/O:(A\'WM$0^#[VB(?!][1$/@^]HB'P?>T1>GP_#]?;O\`GOOO
$HB__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
